Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/22/2/245/410054/mdq684.pdf
Reference14 articles.
1. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents;Bellmunt;Crit Rev Oncol Hematol,2009
2. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99];Albers;Ann Oncol,2011
3. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009
4. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium;Sonpavde;Lancet Oncol,2010
5. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study;Vaughn;Cancer,2009
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Section VI. Chemotherapy for Metastatic Bladder Cancer;Bladder Cancer;2018
2. Molecular Targeted Therapy of Bladder Cancer;Molecular Pathology Library;2017-09-18
3. Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies;Clinical Genitourinary Cancer;2017-08
4. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer;OncoTargets and Therapy;2017-03
5. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model;Clinical Genitourinary Cancer;2016-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3